Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir Activity on HCV in HIV/HCV Co-infected Subjects
NCT01222611Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Mar 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fosamprenavir in hepatitis C (HCV) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoints: HCV Viral load at 48 weeks and Changes in HCV protease gene at 48 weeks. Started Mar 2011; status: completed.
02
Drugs
fosamprenavir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01222611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222611.